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The author of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following correction.

On page 6 there is to be a change to the labelling of **Table 2** footnotes. "**Table 2** Characteristics of patients with sorafenib-associated facial acneiform facial eruptions" is to be replaced with the following: Table 2Characteristics of patients with sorafenib-associated facial acneiform facial eruptionsCase \[Ref.\]1 \[37\]2 \[38\] C13 \[39\]4 \[38\] C25 CRAge (years)4251526579RaceNSWhiteWhiteWhiteAsianSexFemaleMaleMaleMaleMaleCaLEHmRCCmRCmRCCHCCFAL++^b^++^d^+^f^OSALTrunk (upper)Arms, axillae, back (upper), chest (upper)Genital area, neck, scalp----Symptoms--Burning sensation, oiliness (increased), pruritusPainOiliness (increased)--Lesion morphPapules, pustulesOpen comedones = closed comedones (Ca-L)Papules, pustulesOpen comedones = closed comedones (Ca-L)Open comedones \> closed comedones (Ca-L)Soraf dose400 mg BID × 4 weeks, then 800 mg BID400 mg BID600 mg QD400 mg BID400 mg BIDOnset^a^4.16481.3OSCAENSNSAlopecia, HFSR, SFFH, Sp-lNSAlopecia, HFSR, ISK, SD-LE, xerosisTreatmentCleared 2 weeks after Soraf dose lowered to 400 mg BID70% improvement after BP × 2 monthsImprovement after oral tetracycline and topical: BP, EES, Flu, and MetTret 0.05%Clin, Tret 0.025%CommentPt died 2 months after lowering dose of Soraf from cancer prog^c^Soraf stopped for surgery; ACE reappeared when restarted sorafExposure to Agent Orange in Vietnam^e^Lesions slowly resolving with topical therapy after stop Soraf*ACE* acneiform eruption, *BID* twice daily, *BP* benzoyl peroxide, *Ca* cancer, *Ca-L* chloracne-like, *C* case, *Clin* clindamycin 1% solution twice daily, *CR* current report, *EES* erythromycin, *FAL* facial acneiform lesions, *Flu* fluocinonide cream, *HCC* hepatocellular carcinoma, *HFSR* hand--foot skin reaction, *ISK* inflamed seborrheic keratosis, *LEH* liver epithelioid hemangioendothelioma, *Met* metronidazole, *mRC* metastatic renal carcinoma, *mRCC* metastatic renal cell carcinoma, *NS* not stated, *OSAL* other sites of acneiform lesions, *OSCAE* other sorafenib-associated cutaneous adverse events, *prog* progression, *Pt* patient, *QD* daily, *SD-LE* seborrheic dermatitis-like eruption, *SFFH* spiny filiform follicular hyperkeratosis, *soraf* sorafenib, *Sp-l* sandpaper-like skin texture, *Tret 0.025%* tretinoin 0.025% cream each evening, *Tret 0.05%* tretinoin 0.05% cream each evening, + present, − absent^a^Number of weeks on sorafenib prior to appearance of acneiform eruption^b^The facial acneiform lesions were located on bilateral malar cheeks and postauricular areas^c^A skin biopsy of an acneiform lesion showed milia-like cyst with a sparse lymphocytic inflammatory dermal infiltrate^d^The facial acneiform lesions were located on the nose and bilateral malar cheeks, temples and postauricular areas^e^The patient did not return for follow up examination^f^The facial acneiform lesions were located on bilateral malar cheeks, preauricular areas, ears and postauricular areas

The online version of the original article can be found under doi:10.1007/s13555-014-0067-9.
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